Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGT2B7 | P16662 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | MMP9 | P14780 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29809804 | 1.00 | UGT2B7 (0.57) | UGT2B7MEN1KMT2AATMMMP9 | |
| SCHEMBL10381408 | 1.00 | UGT2B7 (0.57) | UGT2B7MEN1KMT2AATMMMP9 | |
| SCHEMBL29594785 | 0.92 | UGT2B7 (0.43) | UGT2B7MEN1KMT2AATMMMP9 | |
| SCHEMBL11801547 | 0.90 | TYR (0.44) | UGT2B7MEN1KMT2AATMMMP9 | |
| SCHEMBL11743708 | 0.86 | TYR (0.44) | UGT2B7MEN1KMT2AATMMMP9 | |
| SCHEMBL11744081 | 0.83 | ESR1 (0.46) | UGT2B7 | |
| SCHEMBL25455654 | 0.82 | CYP2A6 (0.50) | UGT2B7CYP1A2TSHRCYP2A6TDP1 | |
| SCHEMBL11747502 | 0.82 | CYP2A6 (0.50) | UGT2B7CYP1A2TSHRCYP2A6TDP1 | |
| SCHEMBL10650252 | 0.82 | UGT2B7 (0.59) | UGT2B7MEN1KMT2AATMMMP9 | |
| SCHEMBL11704205 | 0.81 | AKR1B1 (0.62) | UGT2B7MEN1KMT2ACYP1A2HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109689848-A | Spice composition | 奇华顿股份有限公司 | 2019-04-26 | — | — | CN | claimed |
| CN-103958047-B | Microcapsules and their use | 弗门尼舍有限公司 | 2017-03-01 | — | — | CN | claimed |
| CN-103958047-A | Microcapsules and their use | FIRMENICH & CIE | 2014-07-30 | — | — | CN | claimed |
| US-20120277164-A1 | GADD45BETA TARGETING AGENTS | IMPERIAL INNOVATIONS LIMITED (GB) | 2012-11-01 | — | — | US | claimed |
| EP-2491051-A2 | GADD45BETA TARGETING AGENTS | Imperial Innovations Limited (GB) | 2012-08-29 | — | — | EP | claimed |
| CN-101076315-B | Sterilization preparation | GIVAUDAN SA | 2012-03-21 | — | — | CN | claimed |
| WO-2011048390-A2 | GADD45BETA TARGETING AGENTS | IMPERIAL INNOVATIONS LIMITED (GB) | 2011-04-28 | — | — | WO | claimed |
| CN-101076315-A | Sterilization preparation | GIVAUDAN SA (CH) | 2007-11-21 | — | — | CN | claimed |
| CN-1228298-C | Perfumery precursor | GIVAUDAN SA (CH) | 2005-11-23 | — | — | CN | claimed |
| CN-1205199-C | Perfume parent | GIVAUDAN SA (CH) | 2005-06-08 | — | — | CN | claimed |
| CN-1160306-C | Slow release of fragrant compounds is perfoumery using 2-benzoyl benzoates, 2-alkanoyl benzoates or alpha-keto esters | — | 2004-08-04 | — | — | CN | claimed |
| US-6380197-B1 | FOR TREATING AND PREVENTING A PLETHORA OF DISEASES INCLUDING DIABETES | AVENTIS PHARMA S. A. (FR) | 2002-04-30 | — | — | US | claimed |
| CN-1330070-A | Perfume parent | GIVAUDAN SA (CH) | 2002-01-09 | — | — | CN | claimed |
| CN-1317475-A | Perfumery precursor | GIVAUDAN SA (CH) | 2001-10-17 | — | — | CN | claimed |
| CN-1302286-A | Slow release of fragrant compounds is perfoumery using 2-benzoyl benzoates, 2-alkanoyl benzoates or alpha-keto esters | FIRMENICH & CIE (CH) | 2001-07-04 | — | — | CN | claimed |
| CN-111936457-B | Enol ether pro-fragrances | 弗门尼舍有限公司 | 2025-02-25 | — | — | CN | disclosed |
| US-12168224-B2 | Optically pure enantiomers of ruthenium complexes and uses thereof | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2024-12-17 | — | — | US | disclosed |
| US-5574171-A | OF VINYL COMPOUNDS TO PRODUCE 2-SUBSTITUTED 1-PROPANALS, A METAL COMPLEX OF A DIPHOSPHINOGLUCOPYRANOSIDE | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1996-11-12 | — | — | US | disclosed |
| US-5475146-A | Reacting vinyl compound with carbon monoxide and hydrogen in presence of catalyst containing cobalt, rhodium, platinum and/or iridium and chiral carbohydrate phosphorus ligand substituted with electron withdrawing groups | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1995-12-12 | — | — | US | disclosed |
| WO-1995006627-A1 | ENANTIOSELECTIVE HYDROFORMYLATION | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1995-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12168224-B2 | Optically pure enantiomers of ruthenium complexes and uses thereof | SQLE, POR, CYP11B2 | UGT2B7 200/4885MEN1 2116/4885KMT2A 4811/4885 |
| US-20120277164-A1 | GADD45BETA TARGETING AGENTS | DDB1, CCL2, DDIT3 | UGT2B7 3583/4885MEN1 2974/4885KMT2A 3039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.